Symbols / RDHL $0.88 -2.37%
RDHL Chart
About
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 4.49M |
| Enterprise Value | 16.22B | Income | -9.31M | Sales | 9.55M |
| Book/sh | -2.45 | Cash/sh | 2866000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 35 | IPO | — |
| P/E | inf | Forward P/E | 29.29 | PEG | — |
| P/S | 0.47 | P/B | -0.36 | P/C | — |
| EV/EBITDA | -1946.30 | EV/Sales | 1698.89 | Quick Ratio | 0.37 |
| Current Ratio | 0.56 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | 0.03 | EPS Growth | — |
| Revenue Growth | 58.60% | Earnings | 2023-04-28 07:00 | ROA | -25.32% |
| ROE | — | ROIC | — | Gross Margin | 64.45% |
| Oper. Margin | -107.33% | Profit Margin | -97.52% | Shs Outstand | 5.11M |
| Shs Float | 15.09B | Short Float | 0.68% | Short Ratio | 0.52 |
| Short Interest | — | 52W High | 3.31 | 52W Low | 0.86 |
| Beta | 4.99 | Avg Volume | 500.90K | Volume | 42.00K |
| Target Price | — | Recom | None | Prev Close | $0.90 |
| Price | $0.88 | Change | -2.37% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.88
Latest analyst target
3. DCF / Fair value
$-14.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.88
Low
—
High
—
Mean
—
- $4M for 30% stake: RedHill Biopharma partners with Cumberland to co-commercialize Talicia in U.S. - Stock Titan Mon, 20 Oct 2025 07
- RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead - Stocktwits hu, 05 Mar 2026 19
- RedHill Biopharma Shareholders Approve RSU Grants and Share Capital Increase - TipRanks hu, 05 Mar 2026 14
- Redhill Biopharma Ltd. (RDHL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Mon, 29 Sep 2025 14
- RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - PR Newswire Mon, 01 Dec 2025 08
- Redhill Biopharma stock soars on GLP-1 side effect treatment progress - Investing.com Nigeria Mon, 05 Jan 2026 13
- RedHill Biopharma (RDHL) Faces Nasdaq Compliance Challenge | RDH - GuruFocus hu, 17 Apr 2025 07
- Is RDHL Poised for Rebound? Analyzing Financial Moves - StocksToTrade Mon, 29 Sep 2025 07
- Redhill Biopharma stock jumps after court win against Kukbo - Investing.com Nigeria Fri, 11 Apr 2025 07
- Is MCHP stock overvalued or fairly priced - July 2025 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn Fri, 06 Mar 2026 21
- $8M 2024 Talicia Revenue — Cumberland to Commercialize FDA‑Approved H. pylori, $4M Investment - Stock Titan Mon, 20 Oct 2025 07
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday - TradingView ue, 28 Nov 2023 08
- Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com ue, 11 Mar 2025 07
- RDHL - Redhill Biopharm Latest Stock News & Market Updates - Stock Titan Wed, 12 Aug 2020 04
- RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma - Stock Titan Mon, 26 Aug 2024 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 11.26M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.23 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.43M | -22.67M | -35.56M | -63.00M |
| TotalUnusualItems | 5.84M | 48.94M | 13.38M | -28.00K |
| TotalUnusualItemsExcludingGoodwill | 5.84M | 48.94M | 13.38M | -28.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.27M | 23.92M | -71.67M | -97.74M |
| ReconciledDepreciation | 619.00K | 1.99M | 8.15M | 18.15M |
| ReconciledCostOfRevenue | 3.19M | 3.46M | 33.34M | 49.41M |
| EBITDA | -7.59M | 26.27M | -22.18M | -63.03M |
| EBIT | -8.21M | 24.28M | -30.34M | -81.18M |
| NetInterestIncome | -1.85M | -2.16M | -42.21M | -16.58M |
| InterestExpense | 55.00K | 367.00K | 41.33M | 16.57M |
| InterestIncome | 133.00K | 94.00K | 140.00K | 51.00K |
| NormalizedIncome | -14.11M | -13.77M | -85.05M | -97.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.27M | 23.92M | -71.67M | -97.74M |
| TotalExpenses | 20.30M | 37.96M | 104.64M | 166.89M |
| TotalOperatingIncomeAsReported | -14.61M | 12.63M | -42.84M | -81.14M |
| DilutedAverageShares | 1.29M | 259.12K | 61.63K | 46.53K |
| BasicAverageShares | 1.29M | 259.12K | 61.63K | 46.53K |
| DilutedEPS | 0.00 | 100.00 | -1.20K | -2.10K |
| BasicEPS | 0.00 | 100.00 | -1.20K | -2.10K |
| DilutedNIAvailtoComStockholders | -8.27M | 23.92M | -71.67M | -97.74M |
| NetIncomeCommonStockholders | -8.27M | 23.92M | -71.67M | -97.74M |
| NetIncome | -8.27M | 23.92M | -71.67M | -97.74M |
| NetIncomeIncludingNoncontrollingInterests | -8.27M | 23.92M | -71.67M | -97.74M |
| NetIncomeContinuousOperations | -8.27M | 23.92M | -71.67M | -97.74M |
| PretaxIncome | -8.27M | 23.92M | -71.67M | -97.74M |
| OtherIncomeExpense | 5.84M | 57.51M | 13.38M | -28.00K |
| OtherNonOperatingIncomeExpenses | 8.56M | |||
| SpecialIncomeCharges | -2.36M | 54.63M | 0.00 | 0.00 |
| GainOnSaleOfBusiness | 35.50M | |||
| OtherSpecialCharges | 2.36M | -19.13M | ||
| GainOnSaleOfSecurity | 8.20M | -5.68M | 13.38M | -28.00K |
| NetNonOperatingInterestIncomeExpense | -1.85M | -2.16M | -42.21M | -16.58M |
| TotalOtherFinanceCost | 1.93M | 1.89M | 1.01M | 65.00K |
| InterestExpenseNonOperating | 55.00K | 367.00K | 41.33M | 16.57M |
| InterestIncomeNonOperating | 133.00K | 94.00K | 140.00K | 51.00K |
| OperatingIncome | -12.25M | -31.43M | -42.84M | -81.14M |
| OperatingExpense | 17.11M | 34.50M | 71.31M | 117.49M |
| OtherOperatingExpenses | -44.06M | |||
| ResearchAndDevelopment | 1.59M | 3.53M | 7.28M | 29.50M |
| SellingGeneralAndAdministration | 15.52M | 30.98M | 64.03M | 87.99M |
| SellingAndMarketingExpense | 1.00M | 2.10M | 9.06M | 11.38M |
| GeneralAndAdministrativeExpense | 14.52M | 28.88M | 54.97M | 76.60M |
| OtherGandA | 6.42M | 10.68M | 20.69M | 32.10M |
| SalariesAndWages | 8.10M | 18.20M | 34.28M | 44.50M |
| GrossProfit | 4.85M | 3.07M | 28.46M | 36.35M |
| CostOfRevenue | 3.19M | 3.46M | 33.34M | 49.41M |
| TotalRevenue | 8.04M | 6.53M | 61.80M | 85.76M |
| OperatingRevenue | 8.04M | 6.53M | 61.80M | 85.76M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 12.90B | 7.87B | 931.96M | 524.02M |
| ShareIssued | 12.90B | 7.87B | 931.96M | 524.02M |
| NetDebt | 95.25M | 54.15M | ||
| TotalDebt | 356.00K | 1.17M | 122.69M | 87.81M |
| TangibleBookValue | -10.23M | -3.51M | -114.03M | -62.77M |
| InvestedCapital | -4.68M | 2.07M | 66.82M | 92.50M |
| WorkingCapital | -10.31M | -3.84M | -111.55M | 7.68M |
| NetTangibleAssets | -10.23M | -3.51M | -114.03M | -62.77M |
| CapitalLeaseObligations | 356.00K | 1.17M | 7.47M | 4.19M |
| CommonStockEquity | -4.68M | 2.07M | -48.40M | 8.88M |
| TotalCapitalization | -4.68M | 2.07M | -48.40M | 92.50M |
| TotalEquityGrossMinorityInterest | -4.68M | 2.07M | -48.40M | 8.88M |
| StockholdersEquity | -4.68M | 2.07M | -48.40M | 8.88M |
| RetainedEarnings | -414.80M | -407.74M | -433.86M | -367.87M |
| AdditionalPaidInCapital | 375.08M | 388.36M | 382.62M | 375.25M |
| CapitalStock | 35.04M | 21.44M | 2.83M | 1.50M |
| CommonStock | 35.04M | 21.44M | 2.83M | 1.50M |
| TotalLiabilitiesNetMinorityInterest | 22.73M | 20.98M | 207.27M | 172.31M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 503.00K | 995.00K | 9.82M | 90.84M |
| OtherNonCurrentLiabilities | 500.00K | 540.00K | 750.00K | 750.00K |
| DerivativeProductLiabilities | 741.00K | 2.62M | 0.00 | |
| TradeandOtherPayablesNonCurrent | 0.00 | 3.90M | ||
| LongTermDebtAndCapitalLeaseObligation | 3.00K | 455.00K | 6.44M | 86.19M |
| LongTermCapitalLeaseObligation | 3.00K | 455.00K | 6.44M | 2.57M |
| LongTermDebt | 83.62M | |||
| CurrentLiabilities | 22.22M | 19.98M | 197.45M | 81.47M |
| OtherCurrentLiabilities | 1.51M | 841.00K | 114.00K | 167.00K |
| CurrentDebtAndCapitalLeaseObligation | 353.00K | 718.00K | 116.25M | 1.62M |
| CurrentCapitalLeaseObligation | 353.00K | 718.00K | 1.03M | 1.62M |
| CurrentDebt | 115.22M | |||
| OtherCurrentBorrowings | 115.22M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 510.00K | 727.00K | 1.67M | 3.50M |
| CurrentProvisions | 9.29M | 10.65M | 47.87M | 30.71M |
| PayablesAndAccruedExpenses | 10.56M | 7.04M | 31.55M | 45.48M |
| CurrentAccruedExpenses | 2.70M | 3.77M | 16.17M | 17.23M |
| Payables | 7.86M | 3.28M | 15.39M | 28.25M |
| OtherPayable | 11.16M | 16.58M | ||
| AccountsPayable | 7.86M | 3.28M | 4.23M | 11.66M |
| TotalAssets | 18.04M | 23.05M | 158.87M | 181.19M |
| TotalNonCurrentAssets | 6.13M | 6.91M | 72.97M | 92.04M |
| OtherNonCurrentAssets | 148.00K | 147.00K | 150.00K | 16.17M |
| GoodwillAndOtherIntangibleAssets | 5.55M | 5.58M | 65.63M | 71.64M |
| OtherIntangibleAssets | 5.55M | 5.58M | 65.63M | 71.64M |
| NetPPE | 437.00K | 1.18M | 7.19M | 4.22M |
| AccumulatedDepreciation | -1.31M | -1.25M | -1.08M | -809.00K |
| GrossPPE | 1.75M | 2.43M | 8.27M | 5.03M |
| Leases | 681.00K | 1.15M | 6.01M | 2.34M |
| OtherProperties | 5.63M | 1.99M | ||
| MachineryFurnitureEquipment | 1.07M | 1.27M | 2.26M | 2.69M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 11.91M | 16.14M | 85.90M | 89.15M |
| RestrictedCash | 0.00 | 790.00K | 16.00M | 0.00 |
| PrepaidAssets | 77.00K | 1.31M | 1.03M | 3.81M |
| Inventory | 3.65M | 4.39M | 11.01M | 14.81M |
| FinishedGoods | 2.83M | 3.33M | 6.83M | 6.60M |
| WorkInProcess | 308.00K | 233.00K | 2.38M | 5.20M |
| RawMaterials | 513.00K | 828.00K | 1.80M | 3.01M |
| Receivables | 3.57M | 4.08M | 37.88M | 32.52M |
| OtherReceivables | 1.03M | 1.49M | 3.35M | 847.00K |
| AccountsReceivable | 2.54M | 2.59M | 34.52M | 31.68M |
| CashCashEquivalentsAndShortTermInvestments | 4.62M | 5.57M | 19.98M | 38.00M |
| OtherShortTermInvestments | 0.00 | 15.00K | 8.53M | |
| CashAndCashEquivalents | 4.62M | 5.57M | 19.97M | 29.47M |
| CashEquivalents | 2.73M | 0.00 | 6.64M | 584.00K |
| CashFinancial | 1.88M | 5.57M | 13.32M | 28.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.38M | -35.83M | -29.38M | -65.16M |
| RepaymentOfDebt | -636.00K | -1.18M | -1.48M | -1.68M |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 8.26M | 13.96M | 23.81M | 78.54M |
| CapitalExpenditure | -9.00K | -11.00K | -198.00K | -115.00K |
| InterestPaidSupplementalData | 55.00K | 367.00K | 8.18M | 11.28M |
| EndCashPosition | 4.62M | 5.57M | 19.97M | 29.47M |
| BeginningCashPosition | 5.57M | 19.97M | 29.47M | 29.30M |
| EffectOfExchangeRateChanges | 9.00K | -22.00K | -76.00K | -96.00K |
| ChangesInCash | -961.00K | -14.38M | -9.43M | 275.00K |
| FinancingCashFlow | 8.42M | 21.44M | 11.45M | 73.46M |
| CashFlowFromContinuingFinancingActivities | 8.42M | 21.44M | 11.45M | 73.46M |
| NetOtherFinancingCharges | 790.00K | 8.65M | -10.88M | -7.40M |
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 4.01M | |
| NetCommonStockIssuance | 8.26M | 13.96M | 23.81M | 78.54M |
| CommonStockIssuance | 8.26M | 13.96M | 23.81M | 78.54M |
| NetIssuancePaymentsOfDebt | -636.00K | -1.18M | -1.48M | -1.68M |
| NetLongTermDebtIssuance | -636.00K | -1.18M | -1.48M | -1.68M |
| LongTermDebtPayments | -636.00K | -1.18M | -1.48M | -1.68M |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -9.00K | 4.00K | 8.30M | -8.14M |
| CashFlowFromContinuingInvestingActivities | -9.00K | 4.00K | 8.30M | -8.14M |
| NetInvestmentPurchaseAndSale | 0.00 | 15.00K | 8.50M | -8.03M |
| SaleOfInvestment | 15.00K | 8.50M | 475.00K | |
| PurchaseOfInvestment | -8.50M | |||
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | ||
| PurchaseOfIntangibles | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -9.00K | -11.00K | -198.00K | -115.00K |
| PurchaseOfPPE | -9.00K | -11.00K | -198.00K | -115.00K |
| OperatingCashFlow | -9.37M | -35.82M | -29.18M | -65.05M |
| CashFlowFromContinuingOperatingActivities | -9.37M | -35.82M | -29.18M | -65.05M |
| ChangeInWorkingCapital | 2.05M | -15.62M | 8.01M | -1.15M |
| ChangeInOtherWorkingCapital | -1.37M | -37.22M | 17.16M | 12.37M |
| ChangeInPayablesAndAccruedExpense | 932.00K | -14.31M | -10.38M | -3.08M |
| ChangeInAccruedExpense | 3.04M | -13.35M | -2.95M | -3.19M |
| ChangeInPayable | -2.11M | -952.00K | -7.43M | 111.00K |
| ChangeInAccountPayable | -2.11M | -952.00K | -7.43M | 111.00K |
| ChangeInPrepaidAssets | 1.70M | 1.59M | 274.00K | 860.00K |
| ChangeInInventory | 738.00K | 2.39M | 3.80M | -8.29M |
| ChangeInReceivables | 52.00K | 31.93M | -2.85M | -3.02M |
| ChangesInAccountReceivables | 52.00K | 31.93M | -2.85M | -3.02M |
| OtherNonCashItems | 2.34M | -543.00K | 33.15M | 5.37M |
| StockBasedCompensation | 665.00K | 1.65M | 5.67M | 10.21M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 5.00K | ||
| DepreciationAmortizationDepletion | 619.00K | 1.99M | 8.15M | 18.15M |
| DepreciationAndAmortization | 619.00K | 1.99M | 8.15M | 18.15M |
| AmortizationCashFlow | 31.00K | 545.00K | 6.02M | 16.23M |
| AmortizationOfIntangibles | 31.00K | 545.00K | 6.02M | 16.23M |
| Depreciation | 588.00K | 1.45M | 2.14M | 1.91M |
| OperatingGainsLosses | -6.78M | -47.21M | -12.50M | 123.00K |
| GainLossOnInvestmentSecurities | -6.77M | 8.85M | -12.46M | 5.00K |
| NetForeignCurrencyExchangeGainLoss | -4.00K | 19.00K | -40.00K | 118.00K |
| GainLossOnSaleOfBusiness | 0.00 | -56.08M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -8.27M | 23.92M | -71.67M | -97.74M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for RDHL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|